<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1716">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01329484</url>
  </required_header>
  <id_info>
    <org_study_id>CPI-AD-TD-CTIL</org_study_id>
    <nct_id>NCT01329484</nct_id>
  </id_info>
  <brief_title>Computerized Personal Interventions for Alzheimer's Patients</brief_title>
  <official_title>Computerized Personal Interventions for Alzheimer's Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shaare Zedek Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shaare Zedek Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the use of computerized systems in 2 common&#xD;
      non pharmacological therapies (cognitive training and reminiscence therapy) will improve the&#xD;
      cognitive function of patients with mild to moderate Alzheimer's disease (AD), or at least&#xD;
      delay its deterioration. In addition, the investigators hypothesize that using the&#xD;
      computerized systems will result in improved well-being of the patients and their main&#xD;
      caregivers / family members, and in improved patient-caregiver and patient-family relations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Reminiscence therapy and cognitive training are two of the most common non-pharmacological&#xD;
      therapies used to treat AD. To date, there is no clear evidence regarding the impact of these&#xD;
      treatments on the cognitive function of people with AD. The inconclusive evidence may be due&#xD;
      to methodological limitations, the availability of a limited number of controlled studies,&#xD;
      the lack of standardized interventions and the need for sensitive assessment tools.&#xD;
&#xD;
      Increasingly, computerized systems are being designed to support both the cognitive&#xD;
      assessment of patients with Alzheimer's disease and the administration of novel&#xD;
      non-pharmacological interventions. Studies suggest that such systems may be of clear benefit.&#xD;
      For example, in an initial study involving patients with AD, computerized cognitive training&#xD;
      systems have been shown to be of value in providing a more standardized approach to cognitive&#xD;
      training. Also, another study found that the use of a computerized system for reminiscence&#xD;
      therapy was successful in facilitating patient-caregiver interaction.&#xD;
&#xD;
      Our research is a collaborative effort designed to test the effects of two such&#xD;
      computer-supported interventions in patients with mild AD. The purpose of the research is to&#xD;
      compare the efficacy of personalized computerized reminiscence therapy and that of&#xD;
      computerized cognitive training to a control group. The reminiscence therapy program is based&#xD;
      on developing an internet-based personalized reminiscence system, which will facilitate&#xD;
      flexible interactive use by patients and caregivers. The importance of a personalized system&#xD;
      is especially salient in immigrant, or in highly mobile, societies due to the heterogeneous&#xD;
      background of the patients.&#xD;
&#xD;
      Separate preliminary studies have found positive effects of each system. The research will&#xD;
      use various measures to evaluate the efficacy of both treatments, including the Mindstreams&#xD;
      (NeuroTrax Corp., NJ) computerized neuropsychological assessment instrument, which will serve&#xD;
      as the cognitive outcome measure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">September 2012</completion_date>
  <primary_completion_date type="Anticipated">September 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive function measured by Mindstreams (NeuroTrax Corp., NJ) computerized neuropsychological assessment instrument.</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cognitive function measured by Mindstreams (NeuroTrax Corp., NJ) computerized neuropsychological assessment instrument.</measure>
    <time_frame>Baseline+1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cognitive function measured by Mindstreams (NeuroTrax Corp., NJ) computerized neuropsychological assessment instrument.</measure>
    <time_frame>Baseline+3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cognitive function measured by Mindstreams (NeuroTrax Corp., NJ) computerized neuropsychological assessment instrument.</measure>
    <time_frame>Baseline+6 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">159</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Cognitive training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Reminiscence therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This group will receive neither of the above interventions or any other similar interventions</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Reminiscence therapy</intervention_name>
    <description>Personalized reminiscence therapy using a computerized system</description>
    <arm_group_label>Reminiscence therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive training</intervention_name>
    <description>Cognitive training using a computerized system</description>
    <arm_group_label>Cognitive training</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No treatment</intervention_name>
    <description>Participants in the control group will receive neither of the 2 experimental interventions or any other similar interventions.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of Alzheimer's Disease&#xD;
&#xD;
          -  MMSE score of 14-26&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Visual impairment&#xD;
&#xD;
          -  Auditory impairment&#xD;
&#xD;
          -  Psychiatric disorders&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tzvi Dwolatzky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mental Health Center, Beer-Sheva</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mental Health Center</name>
      <address>
        <city>Beer Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memory Clinic, Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <study_first_submitted>March 30, 2011</study_first_submitted>
  <study_first_submitted_qc>April 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2011</study_first_posted>
  <last_update_submitted>April 3, 2011</last_update_submitted>
  <last_update_submitted_qc>April 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Tzvi Dwolatzky</name_title>
    <organization>Mental Health Center, Beer-Sheva</organization>
  </responsible_party>
  <keyword>Alzheimer</keyword>
  <keyword>Dementia</keyword>
  <keyword>Computer</keyword>
  <keyword>Cognitive training</keyword>
  <keyword>Reminiscence therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

